Medilax (Glycerol)

Glycerol works by remaining largely unabsorbed in the gut, creating an osmotic gradient that draws water into the bowel. The added fluid softens the stool, expands its volume, and stimulates peristaltic movements, which together promote a smoother and quicker bowel evacuation.

The appropriate dose of Medilax is determined by a qualified healthcare professional based on the patient’s age, severity of constipation, and clinical response. Prescribers select the amount and frequency that best matches the individual’s needs and medical condition.

The safety of glycerol‑based rectal laxatives like Medilax during pregnancy or lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using the product to weigh potential benefits against unknown risks.

To order Medilax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with stimulant laxatives, glycerol‑based products such as Medilax act osmotically, drawing water into the bowel rather than stimulating intestinal muscles. This generally results in a gentler, more physiologic effect with fewer systemic side effects, making it a preferred option for mild to moderate constipation.

Medilax should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability and effectiveness.

Medilax is administered rectally. The prescribed amount is introduced into the rectum, typically using a syringe or applicator, allowing the glycerol solution to contact the intestinal lining. Patients should follow the prescriber’s instructions regarding positioning and duration of contact.

The most serious risks include severe abdominal pain that may signal intestinal obstruction, rectal bleeding from mucosal irritation, and rare allergic reactions such as rash, swelling or anaphylaxis. Any of these symptoms require immediate medical attention.

Medilax should be avoided by individuals with known intestinal obstruction, perforation, severe inflammatory bowel disease, or a documented hypersensitivity to glycerol. Patients with these conditions should seek alternative treatments under medical supervision.